Revolution Medicines, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Revolution Medicines, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Revolution Medicines, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$156M, a 44.1% decline year-over-year.
  • Revolution Medicines, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$567M, a 71.1% decline year-over-year.
  • Revolution Medicines, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$436M, a 75.5% decline from 2022.
  • Revolution Medicines, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$249M, a 32.9% decline from 2021.
  • Revolution Medicines, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$187M, a 73% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$567M -$156M -$47.9M -44.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$519M -$133M -$34.9M -35.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 -$484M -$116M -$47.9M -70.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 -$436M -$162M -$105M -186% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 -$331M -$108M -$35.1M -47.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$296M -$98.3M -$37.1M -60.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$259M -$68.1M -$10.5M -18.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$249M -$56.5M -$3.83M -7.27% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 -$245M -$73.3M -$20.4M -38.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$224M -$61.2M -$16.9M -38.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-06
Q1 2022 -$208M -$57.6M -$20.5M -55.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-06
Q4 2021 -$187M -$52.7M -$18.5M -54% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 -$169M -$52.9M -$25.7M -94.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$143M -$44.3M -$17.1M -62.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$126M -$37.2M -$17.7M -90.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$108M -$34.2M -$19.6M -134% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-02
Q3 2020 -$88.6M -$27.2M -$14.4M -112% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$74.1M -$27.2M -$17.1M -169% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$57.1M -$19.5M -$9.39M -92.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$47.7M -$14.6M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-02
Q3 2019 -$12.8M Jul 1, 2019 Sep 30, 2019 10-K 2021-03-02
Q2 2019 -$10.1M Apr 1, 2019 Jun 30, 2019 10-K 2021-03-02
Q1 2019 -$10.1M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.